Drug Development and Drug Delivery Consultant

Technical Consultant #1406

Functional properties of IgA.
Development of oral vaccine delivery technologies.
Effectiveness of host-parasite relationships.
Mechanisms of adherence and pathogenisis.
Transport of macromolecules across the intestinal epithelium.
Receptor mediated endocytosis.
Isolation, purification and refolding of proteins produced by recombinant DNA technology, including disulfide formation.
Covalent conjugation of peptides and proteins to carriers for oral delivery and to immunostimulatory molecules for parenteral delivery.
Studies on mechanisms of controlled release of bioactive molecules from microspheres and other polymer systems.
Development of oral drug delivery systems.
Development of biodegradable nanoparticles.
Development of targeted delivery systems.
AsialoGlycoProtein receptor.
Development of tumor targeting agents.
Development of transdermal drug delivery systems.
Development of oral nanolattices for protein drugs.

Undisclosed, Science Director, Australia, 2005 - 2007

Road show presentations of transdermal and oral technologies to corporate and individual investors.
Identification of potential business opportunities for in-house ransdermal and oral technology, including market research and identification and assessment of competitive technologies.
Development of transdermal drug delivery systems for insulin, IGF1, GHRP-6, THC, AdeCbl (NO scavenger), EGF.
Development of topical anti-inflammatory molecules.
Development of novel nanolattice systems for oral delivery of proteins (insulin, anti-TNF molecules).
Investigation of the ability of riboflavin to act as a targeting agent for oral delivery.
Investigation of alternative UVA and UVB sunscreen agents.
Development of a topical melanoma vaccine.
Planning, set-up and establishment of animal house and staff training.

Access Pharmaceuticals, Australia, Director/Vice President 2002 - 2005

Investigation into the ability of folate, biotin and vitamin B12 to target imaging agents and cytotoxics (Platinum, Daunomycin, Methotrexate, Gallium) to tumor cells.
Development of targeted delivery system for Inflammatory conditions.
Management of research team, generation, preparation and maintenance of IP.
Planning, set-up and establishment of the Access AEC, animal house, training of animal house staff.

Biotech Australia Pty. Ltd., 1983 - 2001

Manager, Targeted Delivery Group, 2001

Development of oral delivery systems for peptides, proteins, hormones, drugs enveloped in nanoparticles.
Development of vitamin-mediated targeting system for cancer treatment.
Investigation into the ability of folate, biotin and vitamin B12 to target imaging agents and cytotoxics to tumor cells.
Development of an alternative to PEG.
Development of an oral form of GHRP.
Development of an immunological desensitizing agent.

Project Manager/Skill Group Manager Immunochemistry, 1999

Development of oral delivery systems for peptides, proteins, hormones, drugs enveloped in nanoparticles.
Development of an immunocastration vaccine for dogs and cats.
Development of oral vaccine technology.
Management of research team, generation, preparation and maintenance of IP.

Senior Principal Research Scientist, 1993

Development of oral delivery systems for G-CSF and EPO (collaboration with Amgen, 1000 Oaks).
Development of an oral delivery system for gamma Interferon (collaboration with Roche, Basel)
Development of an oral delivery system for Insulin (collaboration with Hoechst, Frankfurt).
Development of controlled release formulations for vaccines.
Management of research team, generation, preparation and maintenance of IP.

Principal Research Scientist, 1989

Development of oral delivery systems for peptides, hormones and drugs.
Development of an immunological castration system for dogs and cats.
Management of research team, generation, preparation and maintenance of IP. Presentation of reports, maintenance of International Collaborations.